Cite
HARVARD Citation
Pant, S. et al. (n.d.). 283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs). Journal for immunotherapy of cancer. p. A309. [Online].